Bristol-Myers Announces Favorable Phase I/II Opdivo Trial Results

(RTTNews) - Bristol-Myers Squibb Co. (BMY) on Friday announced results from an interim analysis of CA209-040, a Phase I/II dose-ranging trial evaluating the safety and anti-tumor activity of Opdivo in previously-treated patients with hepatocellular carcinoma or advanced liver cancer.

Initial findings showed that the estimated survival rate in evaluable patients was 62% at 12 months. Results also show the safety profile of Opdivo is generally consistent with that previously-reported for Opdivo in other tumor types.

More than 700,000 people around the world are diagnosed with hepatocellular carcinoma each year with a majority of all hepatocellular carcinoma cases caused by infection with the hepatitis B virus or hepatitis C virus.

Patients with advanced hepatocellular carcinoma receiving the current standard of care have a median overall survival of less than 1 year. For patients who have relapsed or have disease progression, median survival with best supportive care is about 7 to 8 months.